Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
31 05 2019
Historique:
received: 20 08 2018
accepted: 25 04 2019
entrez: 2 6 2019
pubmed: 4 6 2019
medline: 1 7 2020
Statut: epublish

Résumé

Cancer cells are softer than the normal cells, and metastatic cells are even softer. These changes in biomechanical properties contribute to cancer progression by facilitating cell movement through physically constraining environments. To identify properties that enabled passage through physical constraints, cells that were more efficient at moving through narrow membrane micropores were selected from established cell lines. By examining micropore-selected human MDA MB 231 breast cancer and MDA MB 435 melanoma cancer cells, membrane fluidity and nuclear elasticity were excluded as primary contributors. Instead, reduced actin cytoskeleton anisotropy, focal adhesion density and cell stiffness were characteristics associated with efficient passage through constraints. By comparing transcriptomic profiles between the parental and selected populations, increased Ras/MAPK signalling was linked with cytoskeleton rearrangements and cell softening. MEK inhibitor treatment reversed the transcriptional, cytoskeleton, focal adhesion and elasticity changes. Conversely, expression of oncogenic KRas in parental MDA MB 231 cells, or oncogenic BRaf in parental MDA MB 435 cells, significantly reduced cell stiffness. These results reveal that MAPK signalling, in addition to tumour cell proliferation, has a significant role in regulating cell biomechanics.This article has an associated First Person interview with the first author of the paper.

Identifiants

pubmed: 31152052
pii: 132/11/jcs224071
doi: 10.1242/jcs.224071
pmc: PMC6589089
pii:
doi:

Substances chimiques

KRAS protein, human 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Cancer Research UK
ID : A18276
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M018776/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A17196
Pays : United Kingdom

Informations de copyright

© 2019. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Références

Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Annu Rev Cell Dev Biol. 2003;19:677-95
pubmed: 14570586
Breast Cancer Res. 2005;7(4):R444-54
pubmed: 15987449
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Circ Res. 2006 Mar 17;98(5):606-16
pubmed: 16543511
Micron. 2007;38(8):824-33
pubmed: 17709250
J Biomech Eng. 2007 Dec;129(6):904-12
pubmed: 18067395
Clin Exp Metastasis. 2009;26(4):273-87
pubmed: 18498004
Nat Nanotechnol. 2007 Dec;2(12):780-3
pubmed: 18654431
Biochem Biophys Res Commun. 2008 Oct 3;374(4):609-13
pubmed: 18656442
Analyst. 2008 Nov;133(11):1498-500
pubmed: 18936825
J Cell Biol. 2009 Nov 16;187(4):481-96
pubmed: 19948497
Cell. 2010 May 14;141(4):559-63
pubmed: 20478246
Med Biol Eng Comput. 2010 Oct;48(10):1043-53
pubmed: 20623199
Cell Cycle. 2010 Aug 1;9(15):3012-21
pubmed: 20714216
Stem Cell Rev. 2011 Jun;7(2):471-7
pubmed: 21188651
Biosci Rep. 2012 Feb;32(1):35-44
pubmed: 21401528
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Nanotechnology. 2008 Sep 24;19(38):384003
pubmed: 21832563
J Pathol. 2012 Jan;226(2):185-99
pubmed: 22006671
Annu Rev Cell Dev Biol. 2012;28:113-35
pubmed: 22804576
Anticancer Res. 1990 Nov-Dec;10(6):1661-6
pubmed: 2285240
Trends Cell Biol. 2012 Oct;22(10):536-45
pubmed: 22871642
Trends Cell Biol. 2013 Apr;23(4):151-9
pubmed: 23277088
Nat Cell Biol. 2013 Jul;15(7):860-71
pubmed: 23748611
Cell Death Differ. 2013 Oct;20(10):1293-305
pubmed: 23787996
PLoS One. 2013 Jun 26;8(6):e67689
pubmed: 23840764
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
Nat Protoc. 2014 Feb;9(2):457-63
pubmed: 24481272
Oncogene. 2015 Feb 19;34(8):996-1005
pubmed: 24632610
Cancer Microenviron. 2014 Dec;7(3):139-52
pubmed: 25304454
Nat Rev Mol Cell Biol. 2014 Dec;15(12):813-24
pubmed: 25355506
Nat Commun. 2015 Jan 22;6:6138
pubmed: 25609380
J Mech Behav Biomed Mater. 2015 Sep;49:105-11
pubmed: 26004036
Soft Matter. 2015 Jul 28;11(28):5719-26
pubmed: 26083581
Nat Commun. 2015 Jun 25;6:7525
pubmed: 26109233
Cold Spring Harb Perspect Biol. 2015 Jul 01;7(7):a019091
pubmed: 26134319
Cancer Res. 2016 Apr 1;76(7):2037-49
pubmed: 26825169
Curr Opin Cell Biol. 2016 Jun;40:32-40
pubmed: 26895141
Cell Signal. 2016 Jun;28(6):561-71
pubmed: 26898828
Cell Adh Migr. 2016 Sep 2;10(5):554-567
pubmed: 27050660
Pharmacol Res. 2017 Mar;117:20-31
pubmed: 27956260
Matrix Biol. 2017 Jan;57-58:178-189
pubmed: 28025167
EMBO Mol Med. 2017 Feb;9(2):198-218
pubmed: 28031255
Genome Biol. 2017 Jan 24;18(1):15
pubmed: 28118844
Biochem Soc Trans. 2017 Feb 8;45(1):229-236
pubmed: 28202677
Mediators Inflamm. 2017;2017:9624760
pubmed: 28210073
Biol Cell. 2017 May;109(5):167-189
pubmed: 28244605
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Am J Clin Dermatol. 2017 Dec;18(6):745-754
pubmed: 28537004
FEBS J. 2018 Jan;285(1):8-27
pubmed: 28548369
Biomed Res Int. 2017;2017:8534371
pubmed: 28785589
Sci Data. 2017 Nov 14;4:170172
pubmed: 29135975
Wiley Interdiscip Rev Syst Biol Med. 2018 Mar;10(2):
pubmed: 29195023
Intravital. 2012 Jul 01;1(1):32-43
pubmed: 29607252
Nat Commun. 2018 Jun 20;9(1):2410
pubmed: 29925875
Science. 1988 Feb 19;239(4842):883-8
pubmed: 3277283
J Appl Physiol (1985). 1993 Jun;74(6):3040-5
pubmed: 8366005
Lancet. 1996 May 18;347(9012):1377-81
pubmed: 8637346
J Biol Chem. 1998 Jul 17;273(29):18623-32
pubmed: 9660836

Auteurs

Dominika A Rudzka (DA)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Giulia Spennati (G)

School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.

David J McGarry (DJ)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Ya-Hua Chim (YH)

School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.

Matthew Neilson (M)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Aleksandra Ptak (A)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

June Munro (J)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Gabriela Kalna (G)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Ann Hedley (A)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Daniela Moralli (D)

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.

Catherine Green (C)

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.

Susan Mason (S)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Karen Blyth (K)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Margaret Mullin (M)

Electron Microscopy Facility, Department of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK.

Huabing Yin (H)

School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.

Michael F Olson (MF)

Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK michael.olson@ryerson.ca.
Institute of Cancer Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH